Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism.
J Virol
; 85(11): 5679-84, 2011 Jun.
Article
in En
| MEDLINE
| ID: mdl-21450833
ABSTRACT
Vesicular stomatitis virus (VSV)-based oncolytic virotherapy has the potential to significantly improve the prognosis of aggressive malignancies such as brain cancer. However, VSV's inherent neurotoxicity has hindered clinical development so far. Given that this neurotropism is attributed to the glycoprotein VSV-G, VSV was pseudotyped with the nonneurotropic envelope glycoprotein of the lymphocytic choriomeningitis virus (LCMV-GPâVSV-GP). Compared to VSV, VSV-GP showed enhanced infectivity for brain cancer cells in vitro while sparing primary human and rat neurons in vitro and in vivo, respectively. In conclusion, VSV-GP has a much wider therapeutic window than VSV and is thus more suitable for clinical applications, especially in the brain.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Viral Proteins
/
Glycoproteins
/
Neuroglia
/
Vesiculovirus
/
Oncolytic Viruses
/
Viral Tropism
/
Lymphocytic choriomeningitis virus
Limits:
Animals
/
Humans
Language:
En
Journal:
J Virol
Year:
2011
Type:
Article
Affiliation country:
Austria